The FDA's U-turn on peptides could boost the next telehealth boom [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
The FDA is expected to allow compounding pharmacies to produce 14 injectable peptides, in a reversal from its previous ban on the substances, according to a New York Times report. The agency's reversal on peptides, which are short amino acid chains, could open up the substances to a huge untapped market. For telehealth companies like Ro Solace and Hims & Hers Health, whose ability to produce compound versions of these weight loss drugs created new business lines, peptides would be an obvious next move. More than 1 in 8 Americans is now taking GLP-1s. The popularity of unregulated peptides has exploded recently, as Silicon Valley techies, social media influencers and government officials alike have touted their purported “wellness” benefits for muscle repair and even attractiveness. Most prominently, US Health Secretary RFK Jr. is a proponent. Imports from China of hormone and peptide compounds, including GLPs, melanotan II and others, reached $328 million in the first nine months
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- CROX vs. CTAS: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
- HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- Hims Data Breach Tests Trust As Valuation Gap Attracts Investors [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMSBusiness Wire
- Hims & Hers' Valuations Back To Earth - Robust Monetization Trends Deserve Reiterated Buy [Seeking Alpha]Seeking Alpha
HIMS
Earnings
- 2/23/26 - Beat
HIMS
Sec Filings
- 4/10/26 - Form 4
- 4/7/26 - Form 4
- 4/6/26 - Form 144
- HIMS's page on the SEC website